Key Takeaways
- Alibaba alongside its American payment processing arm AUS Merchant Services reached a $600 million agreement with the DOJ to settle accusations
- The firms permitted approximately 80,000 unlawful sales of pharmaceuticals and chemical substances from 2016 through 2024, representing over $200 million in total transaction value
- Alibaba must surrender $200 million in proceeds and pay an additional $125 million criminal fine; AUS faces $85 million in penalties plus $190 million forfeiture
- Non-prosecution agreements were secured by both entities, with full admission of accountability
- Federal agents conducted over 40 undercover transactions purchasing prohibited drugs and counterfeiting tools throughout the probe
Shares of Alibaba experienced a 1.78% uptick on Wednesday following the company’s announcement of a $600 million resolution with the United States Department of Justice concerning illicit drug transactions conducted through its marketplace.
Alibaba Group Holding Limited, BABA
The settlement encompasses both Alibaba and AUS Merchant Services, its United States-based payment processing subsidiary.
Under non-prosecution agreements, neither entity will face criminal prosecution. However, both acknowledged their failures and committed to enhancing their regulatory compliance frameworks.
According to the Department of Justice, Alibaba permitted vendors to facilitate approximately 80,000 transactions involving prohibited pharmaceuticals, precursor chemicals, and pill manufacturing machinery spanning from 2016 to 2024.
These illicit sales accounted for a gross merchandise value exceeding $200 million.
Under the settlement terms, Alibaba will relinquish $200 million in proceeds and remit a distinct criminal fine totaling $125 million.
Meanwhile, AUS Merchant Services is required to pay $85 million in financial penalties and forfeit an additional $190 million, culminating in the total $600 million settlement figure.
Throughout the federal investigation, undercover operatives successfully completed more than 40 purchases of banned pharmaceutical products and equipment used for counterfeiting operations directly via Alibaba’s e-commerce platform.
Prosecutors highlighted that certain Alibaba staff members had raised internal red flags questioning the adequacy of the company’s compliance protocols in preventing prohibited transactions. These warnings were inadequately addressed.
Furthermore, Alibaba maintained a private communication channel that certain sellers exploited to facilitate sales of restricted merchandise beyond standard oversight mechanisms.
Payment Processing Failures Identified
AUS Merchant Services acknowledged that its anti-money laundering safeguards and transaction surveillance systems were insufficient to identify criminal conduct.
Even after specific vendors were identified for marketing prohibited merchandise, AUS failed to suspend their accounts, instead redirecting them to Alibaba. At minimum, one flagged merchant persisted in selling illegal products following the initial report.
Settlement Agreement Specifics
“Alibaba and AUS have documented steps taken to improve their screening and compliance and provided a commitment to ongoing cooperation with US law enforcement in the future,” said Assistant Attorney General Tysen Duva.
Both corporations have pledged continued collaboration with the Department of Justice and committed to substantial upgrades in their compliance systems moving forward.
Alibaba characterized the agreement as a “mutually satisfactory resolution” and emphasized that the settlement demonstrates its “full cooperation” during the entire regulatory investigation.
Assistant AG Brett Shumate added: “Today’s resolution reflects the Department of Justice’s commitment to ensuring that companies operating e-commerce and digital payment platforms keep illegal, unapproved, misbranded, and dangerous foreign pharmaceuticals off their marketplaces.”
The infractions addressed in this settlement pertain to violations of the United States Federal Food, Drug, and Cosmetic Act.
